Mangalam Drugs Downgraded to Default; Lacks Cooperation

ECONOMY
Whalesbook Logo
AuthorKavya Nair|Published at:
Mangalam Drugs Downgraded to Default; Lacks Cooperation
Overview

CRISIL has downgraded Mangalam Drugs and Organics Limited to 'Default' (CRISIL D) citing issuer non-cooperation and evidence of default, including overdrawn credit facilities and Covid loan non-payment. The company reported significantly weak Q1 FY2025 financials with substantial losses and negative margins, a stark contrast to FY2024 performance. Investors are warned to exercise extreme caution.

📉 The Financial Deep Dive

CRISIL Ratings has severely downgraded Mangalam Drugs and Organics Limited (MDOL) to 'Crisil D/Crisil D Issuer Not Cooperating' for long-term facilities and 'Crisil D Issuer Not Cooperating' for short-term facilities, effective November 24, 2025. This marks a drastic fall from previous ratings of 'Crisil BB+/Stable' and 'Crisil A4+'.

The downgrade is fundamentally driven by the issuer's non-cooperation and clear evidence of default. MDOL has reportedly overdrawn its cash credit facilities by over 30 days and has failed to meet its obligations on Covid loans. Furthermore, CRISIL noted allegations of MDOL having misrepresented facts regarding its capacity to service upcoming debt.

The company's financial performance has deteriorated significantly. In Q1 FY2025 (ending June 2025), MDOL posted revenue of ₹57.35 Crore, a substantial PAT loss of ₹13.73 Crore, and consequently, negative operating (-7.85%) and net profit margins (-23.94%). This is a sharp reversal from FY2024 (ending March 31, 2024), where the company reported revenue of ₹318.23 Crore, a PAT of ₹6.92 Crore, with operating and net profit margins of 11.41% and 2.18%, respectively.

The rating rationale, based on the "best-available information" due to MDOL's lack of cooperation, carries the 'Issuer Not Cooperating' suffix. This suffix indicates that the rating lacks a forward-looking assessment and investors should treat it with extreme caution. The total bank loan facilities under scrutiny amount to ₹115 Crore.

🚩 Risks & Outlook

The immediate and most critical risk is the default status, which severely impacts the company's ability to access further credit and can trigger covenants on existing debt. The 'Issuer Not Cooperating' suffix means CRISIL lacks updated, cooperative input from the company, making the current assessment potentially incomplete and highlighting management's lack of transparency.

Investors must exercise extreme caution. The company's ability to manage its debt obligations and stabilize its financial performance is highly questionable given the reported defaults and weak quarterly results. Any further developments regarding debt servicing, regulatory actions, or management's response to these issues will be crucial watchpoints.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.